InnoShengKang

InnoShengKang (Changzhou Innoshengkang Biomedical Technology Co., Ltd.) is a Chinese biotechnology company and a core subsidiary of Changzhou Qianhong Biopharma. Founded in 2011 and headquartered in Changzhou, the company specializes in the discovery and development of innovative oral small molecule therapeutics, primarily focusing on oncology and rare genetic diseases. Its research is heavily concentrated on kinase inhibitors, with specific programs targeting the PI3K (PIK3CA) pathway for indications such as Familial Adenomatous Polyposis (FAP) and various solid tumors. The company maintains a robust intellectual property portfolio in medicinal chemistry and cell cycle regulation to support its clinical development goals.